Launching a first-in-human (FIH) clinical trial for a radiopharmaceutical therapy (RLT) presents a unique set of challenges that go far beyond those of a traditional oncology program. From coordinating protocol requirements in the context of isotope availability, to site selection, including radiation compliance, and extensive planning for isotope logistics, sponsors must navigate a complex operational landscape to successfully bring their therapy into the clinic.
In this webinar, our leaders will walk attendees through the critical operational steps required to move a radiopharmaceutical candidate from IND submission to first patient dosing. Drawing on decades of hands-on experience, our experts will break down the essential infrastructure, partnerships, and strategic planning elements required to ensure a smooth FIH launch.
Topics will include global regulatory considerations (FDA, EMA, and beyond), best practices for site readiness and staff training, and how to manage the logistics of radioligand supply chains. Attendees will also gain insights into how companion imaging, dosimetry planning, and patient access strategies can be integrated early to streamline development and reduce risk.
Whether you’re preparing for your first IND or already anticipating clinical startup, this session will offer practical guidance and real-world examples designed to help RLT developers avoid common pitfalls, accelerate timelines, and build a strong foundation for success.
SPEAKERS
Jenny Keppler, MBA
Vice President, Translational Medicine
Jkeppler@td2inc.com
Jenny Keppler brings over 25 years of leadership in radiopharmaceutical development, with deep expertise in radioligand therapy (RLT), translational research, and regulatory strategy. She has played a pivotal role in advancing the field, including serving as Executive Director of the Institute for Clinical PET (now WMIS), where she was the industry lead in gaining FDA approval for FDG and negotiating cGMP standards.
Before joining TD2 Oncology, Ms. Keppler held senior executive roles including COO at CTI Molecular Biomarker and ImaginAb, where she also served as acting VP of Clinical Development. Her career spans academic, CRO, and biotech settings, with successful IND submissions across both small and large molecules, from preclinical through Phase II.
At TD2 Oncology, she leads translational and regulatory strategies for complex oncology programs, including radiopharmaceuticals and targeted therapies. She holds an MBA from USC, a B.S. in Marketing from the University of Phoenix, and an A.S. in Nuclear Medicine Technology. Ms. Keppler is a published expert in PET imaging and diagnostic radiopharmaceuticals.
Sean Carlin, PhD
VP of Translational Sciences at Abdera Therapeutics
Sean Carlin is a seasoned professional in the field of translational sciences, currently serving as VP of Translational Sciences at Abdera Therapeutics since January 2025. Prior to this role, Sean held the position of Principal Scientist at Invicro from February 2022 to March 2025, specializing in radioligand imaging, radiobiology, and the development of preclinical and translational radiotheranostic programs. Sean's academic background includes an Associate Research Professorship at the University of Pennsylvania and various roles at Memorial Sloan Kettering Cancer Center, including Assistant Attending RadioChemist and Senior Research Scientist. Additionally, Sean worked as an Assistant Professor of Radiochemistry and Radiopharmacy at Weill Cornell Medical College from November 2010 until December 2016. Sean earned a BS (Hons) in pharmacology and a PhD in Medicine, both from the University of Glasgow
Theresa Bruce
Strategic Advisor
Theresa Bruce is a seasoned clinical operations executive with over 30 years in clinical research, including more than two decades dedicated to oncology. She brings deep expertise in managing the strategic planning and execution of complex, global oncology trials, from first-in-human through late-phase development. Her experience includes senior leadership roles on major RLT studies, including serving as Head of Europe and Australia for the both VISION trial (PSMA-617) and the Phase I ACTION study (68Ga-PSMA and 225Ac-PSMA). These roles placed her at the forefront of theranostic and alpha-emitting agent development.
She is widely respected for her ability to integrate global regulatory strategy, CRO/vendor oversight, and cross-team collaboration to deliver high-quality clinical outcomes. Theresa’s leadership has advanced programs in solid tumors, hematologic malignancies, and immuno-oncology, with a strong emphasis on trial innovation and operational excellence.
Moderator
Chris Clark
CFO
Chris has over 20 years of experience as a finance and operations leader in life sciences, with extensive cross border M&A, IPO operational and integration experience, specifically within contract research organizations (CROs) and biotech. He has a track record of building expert teams and companies both in the US and Europe having previously worked at Ergomed, MedSource, Chiltern, Ockham and Nexus Oncology.
